Experienced in Progressive Familial Intrahepatic Cholestasis Type 2

Dr. Jaideep Behari

Hepatology
University Of Pittsburgh Physicians
300 Halket St, 
Pittsburgh, PA 
Experienced in Progressive Familial Intrahepatic Cholestasis Type 2
University Of Pittsburgh Physicians
300 Halket St, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jaideep Behari is a Hepatologist in Pittsburgh, Pennsylvania. Dr. Behari is rated as an Experienced provider by MediFind in the treatment of Progressive Familial Intrahepatic Cholestasis Type 2. His top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, Cirrhosis, Liver Transplant, and Endoscopy.

His clinical research consists of co-authoring 75 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hepatology
Licenses
Internal Medicine in PA
Hospital Affiliations
Magee Womens Hospital Of Upmc Health System
Upmc Presbyterian Shadyside
Upmc Altoona
Upmc Passavant
The Washington Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Peak Health
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

UNIVERSITY OF PITTSBURGH PHYSICIANS
300 Halket St, Pittsburgh, PA 15213
Other Locations
UNIVERSITY OF PITTSBURGH PHYSICIANS
200 Lothrop St, Pittsburgh, PA 15213

Additional Areas of Focus

Dr. Behari has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Device, Diagnostic test
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Active_not_recruiting
Publish Date: April 11, 2025
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

75 Total Publications

Integrated Patient Digital and Biomimetic Twins for Precision Medicine: A Perspective.
Integrated Patient Digital and Biomimetic Twins for Precision Medicine: A Perspective.
Journal: Seminars in liver disease
Published: July 04, 2025
Similar Doctors
Advanced in Progressive Familial Intrahepatic Cholestasis Type 2
Dr. Scott M. Naum
Gastroenterology | Hepatology
Advanced in Progressive Familial Intrahepatic Cholestasis Type 2
Dr. Scott M. Naum
Gastroenterology | Hepatology
2115 Chapline St, Suite 101, 
Wheeling, WV 
 (47.9 miles away)
304-234-8046
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Scott Naum is a Gastroenterologist and a Hepatologist in Wheeling, West Virginia. Dr. Naum is rated as an Advanced provider by MediFind in the treatment of Progressive Familial Intrahepatic Cholestasis Type 2. His top areas of expertise are Visceromegaly, Cirrhosis, Progressive Familial Intrahepatic Cholestasis Type 1, Gastrectomy, and Colonoscopy. Dr. Naum is currently accepting new patients.

Experienced in Progressive Familial Intrahepatic Cholestasis Type 2
Dr. Kiran Bambha
Hepatology
Experienced in Progressive Familial Intrahepatic Cholestasis Type 2
Dr. Kiran Bambha
Hepatology

University Of Pittsburgh Physicians

200 Lothrop St, 
Pittsburgh, PA 
 (0.4 miles away)
Languages Spoken:
English
See accepted insurances

Kiran Bambha is a Hepatologist in Pittsburgh, Pennsylvania. Dr. Bambha is rated as an Advanced provider by MediFind in the treatment of Progressive Familial Intrahepatic Cholestasis Type 2. Her top areas of expertise are Hepatitis, Hepatitis C, Non-Alcoholic Fatty Liver Disease, Liver Failure, and Liver Transplant.

Experienced in Progressive Familial Intrahepatic Cholestasis Type 2
Dr. Sayed Yossef
Hepatology
Experienced in Progressive Familial Intrahepatic Cholestasis Type 2
Dr. Sayed Yossef
Hepatology

Triad Health Services LLC

3304 Stones Throw Ave, 
Poland, OH 
 (52.2 miles away)
330-707-1115
Languages Spoken:
English
See accepted insurances

Sayed Yossef is a Hepatologist in Poland, Ohio. Dr. Yossef is rated as a Distinguished provider by MediFind in the treatment of Progressive Familial Intrahepatic Cholestasis Type 2. His top areas of expertise are Esophageal Varices, Visceromegaly, Trichohepatoenteric Syndrome, Endoscopy, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Behari's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile